Current Opinion in Lipidology volume 27, issue 3, P242-248 2016 DOI: 10.1097/mol.0000000000000296 View full text
|
|
Share
Maaike Schilperoort, Geerte Hoeke, Sander Kooijman, Patrick C.N. Rensen

Abstract: Preclinical studies established BAT as an important target to combat cardiometabolic disorders and elucidated underlying mechanisms whereas clinical studies identified therapeutic handles. Development of novel lipid-based PET-CT tracers and identification of translational biomarkers of BAT activity are required as alternatives to [F]fluorodeoxyglucose PET-CT to accelerate clinical development of BAT-activating therapeutic strategies.